BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP, Houchen CW. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology. 2011;9:40. [PMID: 21929751 DOI: 10.1186/1477-3155-9-40] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Shao Y, Li P, Zhu ST, Yue JP, Ji XJ, Ma D, Wang L, Wang YJ, Zong Y, Wu YD, Zhang ST. MiR-26a and miR-144 inhibit proliferation and metastasis of esophageal squamous cell cancer by inhibiting cyclooxygenase-2. Oncotarget. 2016;7:15173-15186. [PMID: 26959737 DOI: 10.18632/oncotarget.7908] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
2 Chandrakesan P, Weygant N, May R, Qu D, Chinthalapally HR, Sureban SM, Ali N, Lightfoot SA, Umar S, Houchen CW. DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition. Oncotarget. 2014;5:9269-9280. [PMID: 25211188 DOI: 10.18632/oncotarget.2393] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
3 Pantazis P, Dimas K, Wyche JH, Anant S, Houchen CW, Panyam J, Ramanujam RP. Preparation of siRNA-encapsulated PLGA nanoparticles for sustained release of siRNA and evaluation of encapsulation efficiency. Methods Mol Biol 2012;906:311-9. [PMID: 22791444 DOI: 10.1007/978-1-61779-953-2_25] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
4 Song M, Yin Y, Zhang J, Zhang B, Bian Z, Quan C, Zhou L, Hu Y, Wang Q, Ni S, Fei B, Wang W, Du X, Hua D, Huang Z. MiR-139-5p inhibits migration and invasion of colorectal cancer by downregulating AMFR and NOTCH1. Protein Cell 2014;5:851-61. [PMID: 25149074 DOI: 10.1007/s13238-014-0093-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 59] [Article Influence: 7.1] [Reference Citation Analysis]
5 Zhang LY, Ho-Fun Lee V, Wong AM, Kwong DL, Zhu YH, Dong SS, Kong KL, Chen J, Tsao SW, Guan XY, Fu L. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis 2013;34:454-63. [PMID: 23125220 DOI: 10.1093/carcin/bgs346] [Cited by in Crossref: 136] [Cited by in F6Publishing: 130] [Article Influence: 13.6] [Reference Citation Analysis]
6 Weygant N, Qu D, Berry WL, May R, Chandrakesan P, Owen DB, Sureban SM, Ali N, Janknecht R, Houchen CW. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1. Mol Cancer 2014;13:103. [PMID: 24885928 DOI: 10.1186/1476-4598-13-103] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 7.3] [Reference Citation Analysis]
7 Weygant N, Ge Y, Qu D, Kaddis JS, Berry WL, May R, Chandrakesan P, Bannerman-Menson E, Vega KJ, Tomasek JJ, Bronze MS, An G, Houchen CW. Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase. Cancer Res 2016;76:4090-9. [PMID: 27287716 DOI: 10.1158/0008-5472.CAN-16-0029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
8 Xiang Y, Yang T, Pang BY, Zhu Y, Liu YN. The Progress and Prospects of Putative Biomarkers for Liver Cancer Stem Cells in Hepatocellular Carcinoma. Stem Cells Int 2016;2016:7614971. [PMID: 27610139 DOI: 10.1155/2016/7614971] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
9 Farooqi AA, de la Roche M, Djamgoz MBA, Siddik ZH. Overview of the oncogenic signaling pathways in colorectal cancer: Mechanistic insights. Semin Cancer Biol. 2019;58:65-79. [PMID: 30633978 DOI: 10.1016/j.semcancer.2019.01.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
10 Mushtaq F, Zhang J, Li J. miR-144 suppresses cell proliferation and invasion in gastric cancer through downregulation of activating enhancer-binding protein 4. Oncol Lett 2019;17:5686-92. [PMID: 31186793 DOI: 10.3892/ol.2019.10214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zha W, Cao L, Shen Y, Huang M. Roles of Mir-144-ZFX pathway in growth regulation of non-small-cell lung cancer. PLoS One 2013;8:e74175. [PMID: 24066116 DOI: 10.1371/journal.pone.0074175] [Cited by in Crossref: 53] [Cited by in F6Publishing: 49] [Article Influence: 5.9] [Reference Citation Analysis]
12 Majidinia M, Darband SG, Kaviani M, Nabavi SM, Jahanban-Esfahlan R, Yousefi B. Cross-regulation between Notch signaling pathway and miRNA machinery in cancer. DNA Repair (Amst) 2018;66-67:30-41. [PMID: 29723707 DOI: 10.1016/j.dnarep.2018.04.002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
13 Li Y, Kong D, Ahmad A, Bao B, Sarkar FH. MicroRNA Targeted Therapy for Overcoming Drug Resistance, Reversal of EMT and Elimination of Cancer Stem Cells in Prostate and Pancreatic Cancer. In: Sarkar FH, editor. MicroRNA Targeted Cancer Therapy. Cham: Springer International Publishing; 2014. pp. 199-217. [DOI: 10.1007/978-3-319-05134-5_12] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Li L, Sureban SM, Houchen CW. Brief report: Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injury. Stem Cells 2014;32:822-7. [PMID: 24123696 DOI: 10.1002/stem.1566] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
15 Yuan X, Wu H, Han N, Xu H, Chu Q, Yu S, Chen Y, Wu K. Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. J Hematol Oncol 2014;7:87. [PMID: 25477004 DOI: 10.1186/s13045-014-0087-z] [Cited by in Crossref: 121] [Cited by in F6Publishing: 122] [Article Influence: 15.1] [Reference Citation Analysis]
16 Gao T, Wang M, Xu L, Wen T, Liu J, An G. DCLK1 is up-regulated and associated with metastasis and prognosis in colorectal cancer. J Cancer Res Clin Oncol. 2016;142:2131-2140. [PMID: 27520310 DOI: 10.1007/s00432-016-2218-0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
17 Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism. Oncotarget 2015;6:37200-15. [PMID: 26468984 DOI: 10.18632/oncotarget.5808] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
18 Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma. Int J Oncol 2017;51:91-103. [PMID: 28560410 DOI: 10.3892/ijo.2017.4021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
19 Sarkar S, O'Connell MR, Okugawa Y, Lee BS, Toiyama Y, Kusunoki M, Daboval RD, Goel A, Singh P. FOXD3 Regulates CSC Marker, DCLK1-S, and Invasive Potential: Prognostic Implications in Colon Cancer. Mol Cancer Res. 2017;15:1678-1691. [PMID: 28851816 DOI: 10.1158/1541-7786.mcr-17-0287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
20 Du P, Wang J, Han Y, Feng J. Blocking the LncRNA MALAT1/miR-224-5p/NLRP3 Axis Inhibits the Hippocampal Inflammatory Response in T2DM With OSA. Front Cell Neurosci 2020;14:97. [PMID: 32477065 DOI: 10.3389/fncel.2020.00097] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Kang XL, He LR, Chen YL, Wang SB. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis. World J Gastroenterol 2020; 26(43): 6853-6866 [PMID: 33268966 DOI: 10.3748/wjg.v26.i43.6853] [Reference Citation Analysis]
22 O'Connell MR, Sarkar S, Luthra GK, Okugawa Y, Toiyama Y, Gajjar AH, Qiu S, Goel A, Singh P. Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications. Sci Rep. 2015;5:14983. [PMID: 26447334 DOI: 10.1038/srep14983] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.7] [Reference Citation Analysis]
23 Wang J, Wang S, Zhou J, Qian Q. miR-424-5p regulates cell proliferation, migration and invasion by targeting doublecortin-like kinase 1 in basal-like breast cancer. Biomed Pharmacother. 2018;102:147-152. [PMID: 29550638 DOI: 10.1016/j.biopha.2018.03.018] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 9.8] [Reference Citation Analysis]
24 Fayyaz S, Farooqi AA. miRNA and TMPRSS2-ERG do not mind their own business in prostate cancer cells. Immunogenetics 2013;65:315-32. [DOI: 10.1007/s00251-012-0677-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
25 Verissimo CS, Elands R, Cheng S, Saaltink DJ, ter Horst JP, Alme MN, Pont C, van de Water B, Håvik B, Fitzsimons CP, Vreugdenhil E. Silencing of doublecortin-like (DCL) results in decreased mitochondrial activity and delayed neuroblastoma tumor growth. PLoS One 2013;8:e75752. [PMID: 24086625 DOI: 10.1371/journal.pone.0075752] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
26 Gagliardi G, Goswami M, Passera R, Bellows CF. DCLK1 immunoreactivity in colorectal neoplasia. Clin Exp Gastroenterol. 2012;5:35-42. [PMID: 22557932 DOI: 10.2147/ceg.s30281] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 3.8] [Reference Citation Analysis]
27 Chen Y, Gao DY, Huang L. In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Adv Drug Deliv Rev. 2015;81:128-141. [PMID: 24859533 DOI: 10.1016/j.addr.2014.05.009] [Cited by in Crossref: 352] [Cited by in F6Publishing: 334] [Article Influence: 44.0] [Reference Citation Analysis]
28 Kantara C, O'Connell M, Sarkar S, Moya S, Ullrich R, Singh P. Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA. Cancer Res 2014;74:2487-98. [PMID: 24626093 DOI: 10.1158/0008-5472.CAN-13-3536] [Cited by in Crossref: 80] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
29 Kadletz L, Aumayr K, Heiduschka G, Schneider S, Enzenhofer E, Lill C. Overexpression of DCLK1 is predictive for recurrent disease in major salivary gland malignancies. Eur Arch Otorhinolaryngol. 2017;274:467-475. [PMID: 27470117 DOI: 10.1007/s00405-016-4227-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
30 Gagliardi G, Moroz K, Bellows CF. Immunolocalization of DCAMKL-1, a putative intestinal stem cell marker, in normal colonic tissue. Pathol Res Pract 2012;208:475-9. [PMID: 22749579 DOI: 10.1016/j.prp.2012.05.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
31 Khodadadi Kohlan A, Saidijam M, Amini R, Samadi P, Najafi R. Induction of let-7e gene expression attenuates oncogenic phenotype in HCT-116 colorectal cancer cells through targeting of DCLK1 regulation. Life Sci 2019;228:221-7. [PMID: 31075231 DOI: 10.1016/j.lfs.2019.05.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
32 Dobranowski P, Ban F, Contreras-Sanz A, Cherkasov A, Black PC. Perspectives on the discovery of NOTCH2-specific inhibitors. Chem Biol Drug Des 2018;91:691-706. [PMID: 29078041 DOI: 10.1111/cbdd.13132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
33 Wu X, Ruan Y, Jiang H, Xu C. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma. The International Journal of Biochemistry & Cell Biology 2017;85:66-74. [DOI: 10.1016/j.biocel.2017.01.020] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
34 Zhang S, Zhang G, Guo H. DCAMKL1 is associated with the malignant status and poor outcome in bladder cancer. Tumour Biol 2017;39:1010428317703822. [PMID: 28621231 DOI: 10.1177/1010428317703822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 Lv Y, Song G, Wang R, Di L, Wang J. Doublecortin-like kinase 1 is a novel biomarker for prognosis and regulates growth and metastasis in basal-like breast cancer. Biomedicine & Pharmacotherapy 2017;88:1198-205. [DOI: 10.1016/j.biopha.2017.01.082] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
36 Rao CV, Mohammed A. New insights into pancreatic cancer stem cells. World J Stem Cells 2015; 7(3): 547-555 [PMID: 25914762 DOI: 10.4252/wjsc.v7.i3.547] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
37 Liu J, Guo B. RNA-based therapeutics for colorectal cancer: Updates and future directions. Pharmacol Res 2020;152:104550. [PMID: 31866285 DOI: 10.1016/j.phrs.2019.104550] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
38 Chandrakesan P, Roy B, Jakkula LU, Ahmed I, Ramamoorthy P, Tawfik O, Papineni R, Houchen C, Anant S, Umar S. Utility of a bacterial infection model to study epithelial-mesenchymal transition, mesenchymal-epithelial transition or tumorigenesis. Oncogene 2014;33:2639-54. [PMID: 23752178 DOI: 10.1038/onc.2013.210] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 5.2] [Reference Citation Analysis]
39 Kadletz L, Thurnher D, Wiebringhaus R, Erovic BM, Kotowski U, Schneider S, Schmid R, Kenner L, Heiduschka G. Role of cancer stem-cell marker doublecortin-like kinase 1 in head and neck squamous cell carcinoma. Oral Oncology 2017;67:109-18. [DOI: 10.1016/j.oraloncology.2017.02.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
40 Pan Y, Zhang J, Fu H, Shen L. miR-144 functions as a tumor suppressor in breast cancer through inhibiting ZEB1/2-mediated epithelial mesenchymal transition process. Onco Targets Ther 2016;9:6247-55. [PMID: 27785072 DOI: 10.2147/OTT.S103650] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
41 Takiyama A, Tanaka T, Kazama S, Nagata H, Kawai K, Hata K, Otani K, Nishikawa T, Sasaki K, Kaneko M, Emoto S, Murono K, Takiyama H, Nozawa H. DCLK1 Expression in Colorectal Polyps Increases with the Severity of Dysplasia. In Vivo 2018;32:365-71. [PMID: 29475922 DOI: 10.21873/invivo.11247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Wang L, Ho J, Glackin C, Martins-Green M. Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl Oncol 2012;5:344-55. [PMID: 23066443 DOI: 10.1593/tlo.12190] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 4.4] [Reference Citation Analysis]
43 Sureban SM, May R, Qu D, Weygant N, Chandrakesan P, Ali N, Lightfoot SA, Pantazis P, Rao CV, Postier RG. DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer. PLoS One. 2013;8:e73940. [PMID: 24040120 DOI: 10.1371/journal.pone.0073940] [Cited by in Crossref: 86] [Cited by in F6Publishing: 93] [Article Influence: 9.6] [Reference Citation Analysis]
44 Al-Akhrass H, Christou N. The Clinical Assessment of MicroRNA Diagnostic, Prognostic, and Theranostic Value in Colorectal Cancer. Cancers (Basel) 2021;13:2916. [PMID: 34208056 DOI: 10.3390/cancers13122916] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
45 Qu D, May R, Sureban SM, Weygant N, Chandrakesan P, Ali N, Li L, Barrett T, Houchen CW. Inhibition of Notch signaling reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury. Am J Physiol Gastrointest Liver Physiol 2014;306:G404-11. [PMID: 24368703 DOI: 10.1152/ajpgi.00088.2013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
46 Forterre A, Komuro H, Aminova S, Harada M. A Comprehensive Review of Cancer MicroRNA Therapeutic Delivery Strategies. Cancers (Basel) 2020;12:E1852. [PMID: 32660045 DOI: 10.3390/cancers12071852] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 16.5] [Reference Citation Analysis]
47 Ong BA, Vega KJ, Houchen CW. Intestinal stem cells and the colorectal cancer microenvironment. World J Gastroenterol 2014; 20(8): 1898-1909 [PMID: 24587669 DOI: 10.3748/wjg.v20.i8.1898] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
48 Li H, Yang C, Cheng H, Huang S, Zheng Y. CAR-T cells for Colorectal Cancer: Target-selection and strategies for improved activity and safety. J Cancer 2021;12:1804-14. [PMID: 33613769 DOI: 10.7150/jca.50509] [Reference Citation Analysis]
49 Sun L, Bian G, Meng Z, Dang G, Shi D, Mi S. MiR-144 Inhibits Uveal Melanoma Cell Proliferation and Invasion by Regulating c-Met Expression. PLoS One 2015;10:e0124428. [PMID: 25961751 DOI: 10.1371/journal.pone.0124428] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
50 Narayanan A, Srinaath N, Rohini M, Selvamurugan N. Regulation of Runx2 by MicroRNAs in osteoblast differentiation. Life Sci 2019;232:116676. [PMID: 31340165 DOI: 10.1016/j.lfs.2019.116676] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 9.3] [Reference Citation Analysis]
51 Xie Z, Chen G, Zhang X, Li D, Huang J, Yang C, Zhang P, Qin Y, Duan Y, Gong B, Li Z. Salivary microRNAs as promising biomarkers for detection of esophageal cancer. PLoS One 2013;8:e57502. [PMID: 23560033 DOI: 10.1371/journal.pone.0057502] [Cited by in Crossref: 90] [Cited by in F6Publishing: 83] [Article Influence: 10.0] [Reference Citation Analysis]
52 Mohammadinejad R, Dehshahri A, Sagar Madamsetty V, Zahmatkeshan M, Tavakol S, Makvandi P, Khorsandi D, Pardakhty A, Ashrafizadeh M, Ghasemipour Afshar E, Zarrabi A. In vivo gene delivery mediated by non-viral vectors for cancer therapy. J Control Release 2020;325:249-75. [PMID: 32634464 DOI: 10.1016/j.jconrel.2020.06.038] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 19.0] [Reference Citation Analysis]
53 Pan HL, Wen ZS, Huang YC, Cheng X, Wang GZ, Zhou YC, Wang ZY, Guo YQ, Cao Y, Zhou GB. Down-regulation of microRNA-144 in air pollution-related lung cancer. Sci Rep 2015;5:14331. [PMID: 26395400 DOI: 10.1038/srep14331] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
54 Ali N, Chandrakesan P, Nguyen CB, Husain S, Gillaspy AF, Huycke M, Berry WL, May R, Qu D, Weygant N, Sureban SM, Bronze MS, Dhanasekaran DN, Houchen CW. Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases. Oncotarget 2015;6:20327-44. [PMID: 25948779 DOI: 10.18632/oncotarget.3972] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
55 Gzil A, Zarębska I, Jaworski D, Antosik P, Durślewicz J, Maciejewska J, Domanowska E, Skoczylas-Makowska N, Ahmadi N, Grzanka D, Szylberg Ł. The prognostic value of leucine-rich repeat-containing G-protein (Lgr5) and its impact on clinicopathological features of colorectal cancer. J Cancer Res Clin Oncol 2020;146:2547-57. [PMID: 32671503 DOI: 10.1007/s00432-020-03314-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
56 Jin Y, Wang M, Hu H, Huang Q, Chen Y, Wang G. Overcoming stemness and chemoresistance in colorectal cancer through miR-195-5p-modulated inhibition of notch signaling. International Journal of Biological Macromolecules 2018;117:445-53. [DOI: 10.1016/j.ijbiomac.2018.05.151] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
57 Li J, Xia L, Zhou Z, Zuo Z, Xu C, Song H, Cai J. MiR-186-5p upregulation inhibits proliferation, metastasis and epithelial-to-mesenchymal transition of colorectal cancer cell by targeting ZEB1. Arch Biochem Biophys. 2018;640:53-60. [PMID: 29325758 DOI: 10.1016/j.abb.2018.01.002] [Cited by in Crossref: 51] [Cited by in F6Publishing: 53] [Article Influence: 12.8] [Reference Citation Analysis]
58 Sureban SM, May R, Weygant N, Qu D, Chandrakesan P, Bannerman-Menson E, Ali N, Pantazis P, Westphalen CB, Wang TC, Houchen CW. XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism. Cancer Lett. 2014;351:151-161. [PMID: 24880079 DOI: 10.1016/j.canlet.2014.05.011] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 7.9] [Reference Citation Analysis]
59 Bhadra U, Patra P, Chhatai J, Pal-Bhadra M. Pigmy MicroRNA: surveillance cops in Therapies kingdom. Mol Med 2016;22:759-75. [PMID: 27704139 DOI: 10.2119/molmed.2016.00136] [Reference Citation Analysis]
60 Fernandes M, Marques H, Teixeira AL, Medeiros R. miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin’s Lymphoma: Moving towards an RNA-Guided Precision Medicine. Cancers 2021;13:6324. [DOI: 10.3390/cancers13246324] [Reference Citation Analysis]
61 Tao H, Tanaka T, Okabe K. Doublecortin and CaM kinase-like-1 expression in pathological stage I non-small cell lung cancer. J Cancer Res Clin Oncol 2017;143:1449-59. [DOI: 10.1007/s00432-017-2405-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
62 Lou N, Ruan AM, Qiu B, Bao L, Xu YC, Zhao Y, Sun RL, Zhang ST, Xu GH, Ruan HL, Yuan CF, Han WW, Shi HC, Yang HM, Zhang XP. miR-144-3p as a novel plasma diagnostic biomarker for clear cell renal cell carcinoma. Urol Oncol 2017;35:36.e7-36.e14. [PMID: 27633984 DOI: 10.1016/j.urolonc.2016.07.012] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 4.5] [Reference Citation Analysis]
63 Sureban SM, Berahovich R, Zhou H, Xu S, Wu L, Ding K, May R, Qu D, Bannerman-Menson E, Golubovskaya V, Houchen CW. DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers. Cancers (Basel) 2019;12:E54. [PMID: 31878090 DOI: 10.3390/cancers12010054] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
64 Liu W, Wang S, Sun Q, Yang Z, Liu M, Tang H. DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer.Int J Cancer. 2018;142:2068-2079. [PMID: 29277893 DOI: 10.1002/ijc.31232] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 9.5] [Reference Citation Analysis]
65 Murphy CP, Singewald N. Potential of microRNAs as novel targets in the alleviation of pathological fear. Genes, Brain and Behavior 2018;17:e12427. [DOI: 10.1111/gbb.12427] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
66 Yuan X, Wu H, Xu H, Xiong H, Chu Q, Yu S, Wu GS, Wu K. Notch signaling: an emerging therapeutic target for cancer treatment. Cancer Lett. 2015;369:20-27. [PMID: 26341688 DOI: 10.1016/j.canlet.2015.07.048] [Cited by in Crossref: 204] [Cited by in F6Publishing: 202] [Article Influence: 29.1] [Reference Citation Analysis]
67 Nguyen CB, Houchen CW, Ali N. APSA Awardee Submission: Tumor/cancer stem cell marker doublecortin-like kinase 1 in liver diseases. Exp Biol Med (Maywood) 2017;242:242-9. [PMID: 27694285 DOI: 10.1177/1535370216672746] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
68 Guan H, Liang W, Xie Z, Li H, Liu J, Liu L, Xiu L, Li Y. Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine 2015;48:566-74. [PMID: 24968735 DOI: 10.1007/s12020-014-0326-7] [Cited by in Crossref: 49] [Cited by in F6Publishing: 55] [Article Influence: 6.1] [Reference Citation Analysis]
69 Li L, Bellows CF. Doublecortin-like kinase 1 exhibits cancer stem cell-like characteristics in a human colon cancer cell line. Chin J Cancer Res. 2013;25:134-142. [PMID: 23592893 DOI: 10.3978/j.issn.1000-9604.2013.03.02] [Cited by in F6Publishing: 14] [Reference Citation Analysis]
70 Kalantari E, Asadi Lari MH, Roudi R, Korourian A, Madjd Z. Lgr5High/DCLK1High phenotype is more common in early stage and intestinal subtypes of gastric carcinomas. CBM 2017;20:563-73. [DOI: 10.3233/cbm-170383] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
71 Xie Y, Yi Y, Hu X, Shangguan M, Wang L, Lu Y, Qi J, Wu W. Synchronous microencapsulation of multiple components in silymarin into PLGA nanoparticles by an emulsification/solvent evaporation method. Pharm Dev Technol 2016;21:672-9. [PMID: 25970128 DOI: 10.3109/10837450.2015.1045616] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
72 Shan C, Fei F, Li F, Zhuang B, Zheng Y, Wan Y, Chen J. miR-448 is a novel prognostic factor of lung squamous cell carcinoma and regulates cells growth and metastasis by targeting DCLK1. Biomedicine & Pharmacotherapy 2017;89:1227-34. [DOI: 10.1016/j.biopha.2017.02.017] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
73 Shafiei S, Kalantari E, Saeednejad Zanjani L, Abolhasani M, Asadi Lari MH, Madjd Z. Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas. Exp Mol Pathol 2019;108:164-72. [PMID: 31028726 DOI: 10.1016/j.yexmp.2019.04.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
74 Mohammadi Y, Tavangar SM, Saidijam M, Amini R, Etemadi K, Karimi Dermani F, Najafi R. DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c. Biomed Pharmacother 2018;103:301-7. [PMID: 29656186 DOI: 10.1016/j.biopha.2018.04.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
75 Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, Wang K, Zheng S, Ng SS, Chan FK, Sung JJ, Yu J. microRNA-139-5p exerts tumor suppressor function by targeting NOTCH1 in colorectal cancer. Mol Cancer 2014;13:124. [PMID: 24885920 DOI: 10.1186/1476-4598-13-124] [Cited by in Crossref: 84] [Cited by in F6Publishing: 89] [Article Influence: 10.5] [Reference Citation Analysis]
76 Cordani M, Strippoli R, Somoza Á. Nanomaterials as Inhibitors of Epithelial Mesenchymal Transition in Cancer Treatment. Cancers (Basel) 2019;12:E25. [PMID: 31861725 DOI: 10.3390/cancers12010025] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
77 Mutoh H, Sashikawa M, Sakamoto H, Tateno T. Cyclooxygenase 2 in gastric carcinoma is expressed in doublecortin- and CaM kinase-like-1-positive tuft cells. Gut Liver 2014;8:508-18. [PMID: 25228975 DOI: 10.5009/gnl13237] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
78 Wang X, Yang Y, Huycke MM. Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms. Free Radical Biology and Medicine 2017;105:3-15. [DOI: 10.1016/j.freeradbiomed.2016.10.504] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
79 Han B, Feng D, Yu X, Liu Y, Yang M, Luo F, Zhou L, Liu F. MicroRNA-144 mediates chronic inflammation and tumorigenesis in colorectal cancer progression via regulating C-X-C motif chemokine ligand 11. Exp Ther Med 2018;16:1935-43. [PMID: 30186421 DOI: 10.3892/etm.2018.6389] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
80 Lin L, Zheng Y, Tu Y, Wang Z, Liu H, Lu X, Xu L, Yuan J. MicroRNA-144 suppresses tumorigenesis and tumor progression of astrocytoma by targeting EZH2. Hum Pathol 2015;46:971-80. [PMID: 25907866 DOI: 10.1016/j.humpath.2015.01.023] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
81 Zhou M, Wu Y, Li H, Zha X. MicroRNA-144: A novel biological marker and potential therapeutic target in human solid cancers. J Cancer 2020;11:6716-26. [PMID: 33046994 DOI: 10.7150/jca.46293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Nishio K, Kimura K, Amano R, Nakata B, Yamazoe S, Ohira G, Miura K, Kametani N, Tanaka H, Muguruma K, Hirakawa K, Ohira M. Doublecortin and CaM kinase-like-1 as an independent prognostic factor in patients with resected pancreatic carcinoma. World J Gastroenterol 2017; 23(31): 5764-5772 [PMID: 28883702 DOI: 10.3748/wjg.v23.i31.5764] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
83 Sousa AR, Oliveira AV, Oliveira MJ, Sarmento B. Nanotechnology-based siRNA delivery strategies for metastatic colorectal cancer therapy. International Journal of Pharmaceutics 2019;568:118530. [DOI: 10.1016/j.ijpharm.2019.118530] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
84 Fan M, Qian N, Dai G. Expression and prognostic significance of doublecortin-like kinase 1 in patients with hepatocellular carcinoma. Oncol Lett 2017;14:7529-37. [PMID: 29344199 DOI: 10.3892/ol.2017.7082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.2] [Reference Citation Analysis]
85 Jiang D, Xiao C, Xian T, Wang L, Mao Y, Zhang J, Pang J. Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer. Onco Targets Ther 2018;11:1077-86. [PMID: 29535532 DOI: 10.2147/OTT.S157295] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
86 Whorton J, Sureban SM, May R, Qu D, Lightfoot SA, Madhoun M, Johnson M, Tierney WM, Maple JT, Vega KJ. DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma. Dig Dis Sci. 2015;60:509-513. [PMID: 25283374 DOI: 10.1007/s10620-014-3347-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
87 Chandrakesan P, Yao J, Qu D, May R, Weygant N, Ge Y, Ali N, Sureban SM, Gude M, Vega K, Bannerman-Menson E, Xia L, Bronze M, An G, Houchen CW. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells. Mol Cancer. 2017;16:30. [PMID: 28148261 DOI: 10.1186/s12943-017-0594-y] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
88 Da Silva CG, Peters GJ, Ossendorp F, Cruz LJ. The potential of multi-compound nanoparticles to bypass drug resistance in cancer. Cancer Chemother Pharmacol 2017;80:881-94. [PMID: 28887666 DOI: 10.1007/s00280-017-3427-1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 5.2] [Reference Citation Analysis]
89 Cao Z, Weygant N, Chandrakesan P, Houchen CW, Peng J, Qu D. Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment. Cancers (Basel) 2020;12:E3801. [PMID: 33348546 DOI: 10.3390/cancers12123801] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
90 Azizidoost S, Bavarsad MS, Bavarsad MS, Shahrabi S, Jaseb K, Rahim F, Shahjahani M, Saba F, Ghorbani M, Saki N. The role of notch signaling in bone marrow niche. Hematology 2014;20:93-103. [DOI: 10.1179/1607845414y.0000000167] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
91 Liu YH, Tsang JY, Ni YB, Hlaing T, Chan SK, Chan KF, Ko CW, Mujtaba SS, Tse GM. Doublecortin-like kinase 1 expression associates with breast cancer with neuroendocrine differentiation. Oncotarget. 2016;7:1464-1476. [PMID: 26621833 DOI: 10.18632/oncotarget.6386] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
92 Broner EC, Trujillo JA, Korzinkin M, Subbannayya T, Agrawal N, Ozerov IV, Zhavoronkov A, Rooper L, Kotlov N, Shen L, Pearson AT, Rosenberg AJ, Savage PA, Mishra V, Chatterjee A, Sidransky D, Izumchenko E. Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma. Front Oncol 2021;11:677051. [PMID: 34336664 DOI: 10.3389/fonc.2021.677051] [Reference Citation Analysis]
93 Shi W, Li F, Li S, Wang J, Wang Q, Yan X, Zhang Q, Chai L, Li M. Increased DCLK1 correlates with the malignant status and poor outcome in malignant tumors: a meta-analysis. Oncotarget 2017;8:100545-57. [PMID: 29246000 DOI: 10.18632/oncotarget.20129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
94 Westphalen CB, Quante M, Wang TC. Functional implication of Dclk1 and Dclk1-expressing cells in cancer. Small GTPases 2017;8:164-71. [PMID: 27458755 DOI: 10.1080/21541248.2016.1208792] [Cited by in Crossref: 26] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
95 Pan Y, Mao Y, Jin R, Jiang L. Crosstalk between the Notch signaling pathway and non-coding RNAs in gastrointestinal cancers. Oncol Lett 2018;15:31-40. [PMID: 29285185 DOI: 10.3892/ol.2017.7294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
96 Zhang SY, Lu ZM, Lin YF, Chen LS, Luo XN, Song XH, Chen SH, Wu YL. miR-144-3p, a tumor suppressive microRNA targeting ETS-1 in laryngeal squamous cell carcinoma. Oncotarget 2016;7:11637-50. [PMID: 26826553 DOI: 10.18632/oncotarget.7025] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
97 Yu Z, Hu P, Xu Y, Bao Q, Ni D, Wei C, Shi J. Efficient Gene Therapy of Pancreatic Cancer via a Peptide Nucleic Acid (PNA)-Loaded Layered Double Hydroxides (LDH) Nanoplatform. Small 2020;16:e1907233. [PMID: 32406198 DOI: 10.1002/smll.201907233] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]